DNA prime-protein boost using subtype consensus Env was effective in eliciting neutralizing antibody responses against subtype BC HIV-1 viruses circulating in China

References

• Gao F, Liao HX, Hahn BH, Letvin NL, Korber BT, Haynes BF. Centralized HIV-1 envelope immunogens and neutralizing antibodies. Curr HIV Res 2007; 5:572 - 7; http://dx.doi.org/10.2174/157016207782418498; PMID: 18045113
   PubMed Web of Science ®Google Scholar
• Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma B, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005; 79:1154 - 63; http://dx.doi.org/10.1128/JVI.79.2.1154-1163.2005; PMID: 15613343
   PubMed Web of Science ®Google Scholar
• Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 2007; 360:218 - 34; http://dx.doi.org/10.1016/j.virol.2006.10.017; PMID: 17097711
   PubMed Web of Science ®Google Scholar
• Kothe DL, Li Y, Decker JM, Bibollet-Ruche F, Zammit KP, Salazar MG, et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. Virology 2006; 352:438 - 49; http://dx.doi.org/10.1016/j.virol.2006.05.011; PMID: 16780913
   PubMed Web of Science ®Google Scholar
• Weaver EA, Camacho ZT, Gao F. Similar T-cell immune responses induced by group M consensus env immunogens with wild-type or minimum consensus variable regions. AIDS Res Hum Retroviruses 2010; 26:577 - 84; http://dx.doi.org/10.1089/aid.2009.0258; PMID: 20438382
   PubMed Web of Science ®Google Scholar
• Weaver EA, Lu Z, Camacho ZT, Moukdar F, Liao HX, Ma BJ, et al. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen. J Virol 2006; 80:6745 - 56; http://dx.doi.org/10.1128/JVI.02484-05; PMID: 16809280
   PubMed Web of Science ®Google Scholar
• Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005; 79:7933 - 7; http://dx.doi.org/10.1128/JVI.79.12.7933-7937.2005; PMID: 15919951
   PubMed Web of Science ®Google Scholar
• Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006; 350:34 - 47; http://dx.doi.org/10.1016/j.virol.2006.02.032; PMID: 16616287
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008; 82:7369 - 78; http://dx.doi.org/10.1128/JVI.00562-08; PMID: 18495775
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26:1098 - 110; http://dx.doi.org/10.1016/j.vaccine.2007.12.024; PMID: 18243434
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 2010; 28:2999 - 3007; http://dx.doi.org/10.1016/j.vaccine.2010.02.006; PMID: 20170767
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang SX, Liu SY, Bao ZY, Zhuang DM, Li L, et al. Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of “DNA prime plus protein boost”. Chin Med J (Engl) 2009; 122:2339 - 45; PMID: 20079137
   PubMed Web of Science ®Google Scholar
• Yu XF, Chen J, Shao Y, Beyrer C, Lai S. Two subtypes of HIV-1 among injection-drug users in southern China. Lancet 1998; 351:1250; http://dx.doi.org/10.1016/S0140-6736(05)79316-8; PMID: 9643749
   PubMed Web of Science ®Google Scholar
• Yu XF, Chen J, Shao Y, Beyrer C, Liu B, Wang Z, et al. Emerging HIV infections with distinct subtypes of HIV-1 infection among injection drug users from geographically separate locations in Guangxi Province, China. J Acquir Immune Defic Syndr 1999; 22:180 - 8; PMID: 10843533
   PubMed Web of Science ®Google Scholar
• Graf M, Shao Y, Zhao Q, Seidl T, Köstler J, Wolf H, et al. Cloning and characterization of a virtually full-length HIV type 1 genome from a subtype B’-Thai strain representing the most prevalent B-clade isolate in China. AIDS Res Hum Retroviruses 1998; 14:285 - 8; http://dx.doi.org/10.1089/aid.1998.14.285; PMID: 9491920
   PubMed Web of Science ®Google Scholar
• Li Z, He X, Wang Z, Xing H, Li F, Yang Y, et al. Tracing the origin and history of HIV-1 subtype B’ epidemic by near full-length genome analyses. AIDS 2012; 26:877 - 84; http://dx.doi.org/10.1097/QAD.0b013e328351430d; PMID: 22269972
   PubMed Web of Science ®Google Scholar
• Xin R, He X, Xing H, Sun F, Ni M, Zhang Y, et al. Genetic and temporal dynamics of human immunodeficiency virus type 1 CRF07_BC in Xinjiang, China. J Gen Virol 2009; 90:1757 - 61; http://dx.doi.org/10.1099/vir.0.009290-0; PMID: 19321756
   PubMed Web of Science ®Google Scholar
• Chong H, Hong K, Zhang C, Nie J, Song A, Kong W, et al. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China. J Acquir Immune Defic Syndr 2008; 47:535 - 43; http://dx.doi.org/10.1097/QAI.0b013e3181663967; PMID: 18209676
   PubMed Web of Science ®Google Scholar
• Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 2006; 80:2515 - 28; http://dx.doi.org/10.1128/JVI.80.5.2515-2528.2006; PMID: 16474158
   PubMed Web of Science ®Google Scholar
• Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, Jiang P, et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 2007; 366:245 - 62; http://dx.doi.org/10.1016/j.virol.2007.04.033; PMID: 17580087
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856 - 61; http://dx.doi.org/10.1126/science.1187659; PMID: 20616233
   PubMed Web of Science ®Google Scholar
• Douagi I, Forsell MN, Sundling C, O’Dell S, Feng Y, Dosenovic P, et al. Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates. J Virol 2010; 84:1683 - 95; http://dx.doi.org/10.1128/JVI.01896-09; PMID: 19955308
   PubMed Web of Science ®Google Scholar
• Sundling C, O’Dell S, Douagi I, Forsell MN, Mörner A, Loré K, et al. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus. J Virol 2010; 84:9086 - 95; http://dx.doi.org/10.1128/JVI.01015-10; PMID: 20610729
   PubMed Web of Science ®Google Scholar
• Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006; 24:4531 - 40; http://dx.doi.org/10.1016/j.vaccine.2005.08.023; PMID: 16140431
   PubMed Web of Science ®Google Scholar
• Wang S, Taaffe J, Parker C, Solórzano A, Cao H, García-Sastre A, et al. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 2006; 80:11628 - 37; http://dx.doi.org/10.1128/JVI.01065-06; PMID: 16987975
   PubMed Web of Science ®Google Scholar
• Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays. Curr Protoc Immunol 2004; In press PMID: 18432938
   PubMedGoogle Scholar
• Wang Z, Zhang M, Wang Y, Jiao Y, Zhang L, Li L, et al. A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates. J Virol Methods 2011; 171:183 - 9; http://dx.doi.org/10.1016/j.jviromet.2010.10.022; PMID: 21034776
   PubMed Web of Science ®Google Scholar
• Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 2006; 80:8745 - 62; http://dx.doi.org/10.1128/JVI.00956-06; PMID: 16912322
   PubMed Web of Science ®Google Scholar